Literature DB >> 20636540

Investigation of potential carbohydrate antigen targets for human and baboon antibodies.

Peter Yeh1, Mohamed Ezzelarab, Nicolai Bovin, Hidetaka Hara, Cassandra Long, Koji Tomiyama, Frank Sun, David Ayares, Michel Awwad, David K C Cooper.   

Abstract

BACKGROUND: The continued presence of a primate antibody-mediated response to cells and organs from alpha1,3-galactosyltransferase gene-knockout (GTKO) pigs indicates that there may be antigens other than Gal alpha 1,3Gal (alpha Gal) against which primates have xenoreactive antibodies. Human and baboon sera were tested for reactivity against a panel of saccharides that might be potential antigen targets for natural anti-non-alpha Gal antibodies.
METHODS: Human sera (n = 16) and baboon sera (n = 15) of all ABO blood types were tested using an enzyme-linked immunoadsorbent assay for binding of IgM and IgG to a panel of synthetic polyacrylamide-linked saccharides (n = 15). Human sera were also tested after adsorption on alpha Gal immunoaffinity beads. Sera from healthy wild-type (WT, n = 6) and GTKO (n = 6) pigs and from baboons (n = 4) sensitized to GTKO pig organ or artery transplants (of blood type O) were also tested. Forssman antigen expression on baboon and pig tissues was investigated by immunohistochemistry.
RESULTS: Both human and baboon sera showed high IgM and IgG binding to alpha Gal saccharides, alpha-lactosamine, and Forssman disaccharide. Human sera also demonstrated modest binding to N-glycolylneuraminic acid (Neu5Gc). When human sera were adsorbed on alpha Gal oligosaccharides, there was a reduction in binding to alpha Gal and alpha-lactosamine, but not to Forssman. WT and GTKO pig sera showed high binding to Forssman, and GTKO pig sera showed high binding to alpha Gal saccharides. Baboon sera sensitized to GTKO pigs showed no significant increased binding to any specific saccharide. Staining for Forssman was negative on baboon and pig tissues.
CONCLUSIONS: We were unable to identify definitively any saccharides from the selected panel that may be targets for primate anti-non-alpha Gal antibodies. The high level of anti-Forssman antibodies in humans, baboons, and pigs, and the absence of Forssman expression on pig tissues, suggest that the Forssman antigen does not play a role in the primate immune response to pigs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636540     DOI: 10.1111/j.1399-3089.2010.00579.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  28 in total

1.  Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.

Authors:  Hidetaka Hara; Andrew Bentall; Cassandra Long; Jason Fang; Oleg Andreyev; John Lunz; Mohamed Ezzelarab; Kareem M Abu-Elmagd; Ron Shapiro; David Ayares; Mark Stegall; David K C Cooper
Journal:  Xenotransplantation       Date:  2013-09-03       Impact factor: 3.907

2.  Is there a correlation between anti-pig antibody levels in humans and geographic location during childhood?

Authors:  Goutham Kumar; Vikas Satyananda; Jason Fang; Hao Zhou; Minoru Fujita; Burcin Ekser; Cassandra Long; Eefje Dons; Qing Sun; David Ayares; Hidetaka Hara; David K C Cooper
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

3.  Reducing the Threshold for Clinical Renal Xenotransplantation.

Authors:  Peter J Cowan; Francesco L Ierino
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

4.  T-cell-based immunosuppressive therapy inhibits the development of natural antibodies in infant baboons.

Authors:  Eefje M Dons; Claudia Montoya; Cassandra E Long; Hidetaka Hara; Gabriel J Echeverri; Burcin Ekser; Corin Ezzelarab; Dasha Roa Medellin; Dirk J van der Windt; Noriko Murase; Lora H Rigatti; Robert Wagner; Roman F Wolf; Mohamed Ezzelarab; Lori J West; Jan N M Ijzermans; David K C Cooper
Journal:  Transplantation       Date:  2012-04-27       Impact factor: 4.939

5.  The effect of Gal expression on pig cells on the human T-cell xenoresponse.

Authors:  Tyler Wilhite; Corin Ezzelarab; Hidetaka Hara; Cassandra Long; David Ayares; David K C Cooper; Mohamed Ezzelarab
Journal:  Xenotransplantation       Date:  2012 Jan-Feb       Impact factor: 3.907

Review 6.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

7.  Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk.

Authors:  Vered Padler-Karavani; Ajit Varki
Journal:  Xenotransplantation       Date:  2011 Jan-Feb       Impact factor: 3.907

Review 8.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

9.  Carbohydrate antigen expression and anti-pig antibodies in New World capuchin monkeys: Relevance to studies of xenotransplantation.

Authors:  Qi Li; Sahar Shaikh; Hayato Iwase; Cassandra Long; Whayoung Lee; Zhongqiang Zhang; Yi Wang; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Xenotransplantation       Date:  2019-02-16       Impact factor: 3.907

10.  Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Authors:  Whayoung Lee; Hidetaka Hara; Mohamed B Ezzelarab; Hayato Iwase; Rita Bottino; Cassandra Long; Jagdeece Ramsoondar; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-03-14       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.